WO2006020755A3 - Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics - Google Patents
Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics Download PDFInfo
- Publication number
- WO2006020755A3 WO2006020755A3 PCT/US2005/028523 US2005028523W WO2006020755A3 WO 2006020755 A3 WO2006020755 A3 WO 2006020755A3 US 2005028523 W US2005028523 W US 2005028523W WO 2006020755 A3 WO2006020755 A3 WO 2006020755A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- diabetes
- mtor pathway
- identifying inhibitors
- diabetes therapeutics
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60019304P | 2004-08-10 | 2004-08-10 | |
US60/600,193 | 2004-08-10 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006020755A2 WO2006020755A2 (en) | 2006-02-23 |
WO2006020755A9 WO2006020755A9 (en) | 2006-03-23 |
WO2006020755A3 true WO2006020755A3 (en) | 2006-07-06 |
Family
ID=35500665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/028523 WO2006020755A2 (en) | 2004-08-10 | 2005-08-10 | Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006020755A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
JP2008530127A (en) | 2005-02-09 | 2008-08-07 | マクサイト, インコーポレイテッド | Formulation for eye treatment |
AU2007212271B2 (en) | 2006-02-09 | 2012-11-01 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
WO2007112052A2 (en) | 2006-03-23 | 2007-10-04 | Macusight, Inc. | Formulations and methods for vascular permeability-related diseases or conditions |
US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
JP2014520119A (en) * | 2011-06-17 | 2014-08-21 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Methods for increasing insulin sensitivity and methods for treating diabetes |
BR112019027402A2 (en) | 2017-06-22 | 2020-07-07 | Celgene Corporation | treatment of hepatocellular carcinoma characterized by infection with the hepatitis b virus |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020039736A1 (en) * | 2000-06-05 | 2002-04-04 | Byrne Michael C. | Compositions, kits, and methods for identification and modulation of type I diabetes |
WO2002079786A2 (en) * | 2001-03-30 | 2002-10-10 | Biostratum Ab | Method for identifying drugs for the treatment of type ii diabetes |
US20030170287A1 (en) * | 2002-01-10 | 2003-09-11 | Prescott Margaret Forney | Drug delivery systems for the prevention and treatment of vascular diseases |
WO2003104481A2 (en) * | 2002-06-08 | 2003-12-18 | University Of Dundee | Methods |
WO2004035815A1 (en) * | 2002-10-18 | 2004-04-29 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Modulation of s6 kinase activity for the treatment of obestiy |
US20050009112A1 (en) * | 2003-03-07 | 2005-01-13 | Fred Hutchinson Cancer Research Center, Office Of Technology Transfer | Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth |
WO2005019829A1 (en) * | 2003-08-22 | 2005-03-03 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Inhibition of s6 kinase activity for the treatment of insulin resistance |
-
2005
- 2005-08-10 WO PCT/US2005/028523 patent/WO2006020755A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020039736A1 (en) * | 2000-06-05 | 2002-04-04 | Byrne Michael C. | Compositions, kits, and methods for identification and modulation of type I diabetes |
WO2002079786A2 (en) * | 2001-03-30 | 2002-10-10 | Biostratum Ab | Method for identifying drugs for the treatment of type ii diabetes |
US20030170287A1 (en) * | 2002-01-10 | 2003-09-11 | Prescott Margaret Forney | Drug delivery systems for the prevention and treatment of vascular diseases |
WO2003104481A2 (en) * | 2002-06-08 | 2003-12-18 | University Of Dundee | Methods |
WO2004035815A1 (en) * | 2002-10-18 | 2004-04-29 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Modulation of s6 kinase activity for the treatment of obestiy |
US20050009112A1 (en) * | 2003-03-07 | 2005-01-13 | Fred Hutchinson Cancer Research Center, Office Of Technology Transfer | Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth |
WO2005019829A1 (en) * | 2003-08-22 | 2005-03-03 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Inhibition of s6 kinase activity for the treatment of insulin resistance |
Non-Patent Citations (2)
Title |
---|
GUAL P ET AL: "MAP kinases and mTOR mediate insulin-induced phosphorylation of Insulin Receptor Substrate-1 on serine residues 307, 612 and 632.", DIABETOLOGIA, vol. 46, no. 11, November 2003 (2003-11-01), pages 1532 - 1542, XP002361773, ISSN: 0012-186X * |
MANNING B D ET AL: "Rheb fills a GAP between TSC and TOR", TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER, HAYWARDS, GB, vol. 28, no. 11, November 2003 (2003-11-01), pages 573 - 576, XP004471234, ISSN: 0968-0004 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006020755A2 (en) | 2006-02-23 |
WO2006020755A9 (en) | 2006-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20082476L (en) | Bicyclic compounds with kinase inhibitory activity | |
ATE482213T1 (en) | PYRAZOLOÄ1,5-AÜPYRIMIDINES SUITABLE AS INHIBITORS OF PROTEIN KINASES | |
WO2007079164A3 (en) | Protein kinase inhibitors | |
ATE493401T1 (en) | DIAMINOTRIAZOLE COMPOUNDS SUITABLE AS PROTEIN KINASE INHIBITORS | |
TW200633980A (en) | Pyridones useful as inhibitors of kinases | |
WO2009006389A3 (en) | Pyrimidine derivatives useful as raf kinase inhibitors | |
WO2005012241A3 (en) | p-38 KINASE INHIBITORS | |
NO20083918L (en) | Dihydridiazepines useful as inhibitors of protein kinases | |
EA200970403A1 (en) | BICYCLIC TRIAZOLES AS PROTEINKINASE MODULATORS | |
EA200901486A1 (en) | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | |
DE602007007985D1 (en) | AS INHIBITORS OF PROTEIN KINASES SUITABLE AMINO-PRIMIDINES | |
WO2007149427A3 (en) | Tyrosine kinase inhibitors | |
WO2006007378A3 (en) | Pyrrolotriazine kinase inhibitors | |
WO2010009342A3 (en) | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors | |
WO2008083367A3 (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
WO2008076392A3 (en) | Compounds useful as protein kinase inhibitors | |
WO2005086656A3 (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
DE602004024374D1 (en) | COMPOSITIONS FOR USE AS PROTEIN KINASE INHIBITORS | |
WO2005076854A3 (en) | Pyrimidinone compounds useful as kinase inhibitors | |
WO2006020755A3 (en) | Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics | |
WO2010083207A3 (en) | Protein kinase c inhibitors and uses thereof | |
WO2007047447A3 (en) | Diuretic-like compound analogs useful for regulation of central nervous system disorders | |
WO2009038385A3 (en) | Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same | |
EA200901484A1 (en) | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | |
WO2006078574A3 (en) | Mitotic kinesin inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGE 1/1, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |